Up 12% In A Week, What's Happening With AVGO Stock?
Broadcom Inc. (NASDAQ: AVGO) stock has risen 12% over the past five days due to two key developments: a broader market rebound after President Trump suspended reciprocal tariffs for 90 days, and the company's announcement of a $10 billion share buyback program. Despite the recent gains, AVGO is still down over 20% this year. Such fluctuations are not unusual for the stock—AVGO fell 36% during the 2022 inflation-driven downturn and dropped 48% during the COVID-19-related market selloff in 2020. However, for investors seeking a potentially more stable and high-performing alternative, consider the Trefis High Quality Portfolio, which includes 30 stocks with a strong record of consistently outperforming the S&P 500 over the past four years.
Broadcom's key financial indicators highlight its strong foundation:
For long-term investors, the recent decline in AVGO stock could offer a compelling entry point, considering the company's solid fundamentals and AI leadership. Those sensitive to volatility should consider hedging, consulting a financial advisor, or diversification, such as the Trefis Reinforced Value (RV) Portfolio, which has outperformed its all-cap stocks benchmark to produce strong returns for investors. A calm, strategic approach is crucial for wealth generation during market volatility.
Invest with Trefis
Market Beating Portfolios | Rules-Based Wealth
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
29 minutes ago
- Business Insider
With UnitedHealth Group (UNH) Stock Down Over 50%, Let's Look at Who Owns It
UnitedHealth Group (UNH) has had a rough ride in 2025. The stock is down over 56% year-to-date, hit by rising medical costs, a DOJ probe, executive changes, and now disappointing Q2 results. The company recently posted adjusted earnings per share of $4.08 on $111.6 billion in revenue, narrowly beating the revenue forecast but missing the EPS consensus of around $4.45. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Still, the company reaffirmed its full-year guidance and provided more clarity on its 2025–2026 outlook, prompting mixed reactions from analysts. For instance, analyst Lance Wilkes from Bernstein remains optimistic, citing UnitedHealth's strong market position and potential rebound in Medicare Advantage trends. In contrast, BofA analyst Kevin Fischbeck is more cautious, due to concerns over the company's slower growth pace. With the stock in focus, now's a good time to take a closer look at who actually owns UNH shares. Now, according to TipRanks' ownership page, public companies and individual investors own 45.60% of UNH. They are followed by mutual funds, ETFs, other institutional investors, and insiders at 28.84%, 23.20%, 2.19%, and 0.18%, respectively. Digging Deeper into UnitedHealth Group's Ownership Structure Looking closely at top shareholders, Vanguard owns the highest stake in UNH at 8.89%. Next up is Vanguard Index Funds, which holds a 7.03% stake in the company. Among the top ETF holders, the Vanguard Total Stock Market ETF (VTI) owns a 3.22% stake in UNH stock, followed by the Vanguard S&P 500 ETF (VOO), with a 2.84% stake. Moving to mutual funds, Vanguard Index Funds holds about 7.03% of UNH. Meanwhile, Fidelity Concord Street Trust owns 1.72% of the company. Is UNH a Good Buy Now? Turning to Wall Street, UNH stock has a Moderate Buy consensus rating based on 18 Buys, three Holds, and two Sells assigned in the last three months. At $321.76, the average UnitedHealth stock price target implies a 28.93% upside potential.
Yahoo
42 minutes ago
- Yahoo
Buy and Hold Investors Shouldn't Overlook Roper Technologies' (ROP) Consistency
Roper Technologies, Inc. (NASDAQ:ROP) is included among the 10 Best Dividend Stocks to Buy and Hold Forever. A software developer looking out a window while confidently typing away on their laptop. Roper Technologies, Inc. (NASDAQ:ROP) is a group of technology businesses that hold strong positions in specialized niche markets. Its portfolio includes application software, network software, and technology-enabled products, all designed to deliver essential solutions that become deeply integrated into customers' operations. These offerings typically lead to high switching costs and generate steady, recurring revenue. In the second quarter of 2025, Roper Technologies, Inc. (NASDAQ:ROP) reported a 13.2% increase in revenue, driven by 7% organic growth and a 6% boost from recent acquisitions. GAAP net earnings rose by 12%. Management pointed to balanced growth across all major segments, crediting strong product innovation, successful integration of past acquisitions, and ongoing demand for recurring software solutions. Roper Technologies, Inc. (NASDAQ:ROP) has garnered investor attention because the company has a strong dividend policy. On June 11, the company declared a quarterly dividend of $0.825 per share, which was in line with its previous dividend. Overall, it has raised its payouts for 33 consecutive years, which makes ROP one of the best dividend stocks to buy and hold. The stock has a dividend yield of 0.60%, as of July 31. While we acknowledge the potential of ROP as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Forbes
44 minutes ago
- Forbes
How Will VRTX Stock React To Its Upcoming Earnings?
Vertex Pharmaceuticals (NASDAQ:VRTX) is set to release its earnings on Monday, August 4, 2025. Over the last five years, Vertex's stock has displayed a trend of positive one-day returns in 58% of cases following earnings announcements. The median positive return has been 3.0%, with a maximum one-day increase of 9.0%. For those trading based on events, recognizing these historical trends can prove advantageous, although actual performance against expectations will be crucial. There are two primary strategies to think about: Analysts anticipate Vertex will disclose earnings of $4.25 per share, generating a revenue of $2.91 billion. This marks a considerable improvement compared to the same quarter last year, which reported a loss of $12.83 per share on sales of $2.65 billion. However, if you are looking for upside with reduced volatility compared to individual stocks, the Trefis High Quality portfolio offers an alternative – having outperformed the S&P 500 and achieved returns exceeding 91% since its launch. View earnings reaction history of all stocks Vertex Pharmaceuticals' Historical Probability of Positive Post-Earnings Return Some insights regarding one-day (1D) post-earnings returns: Further information on observed 5-Day (5D) and 21-Day (21D) returns following earnings is summarized in the table below along with the related statistics. Correlation Between 1D, 5D and 21D Historical Returns A comparatively lower-risk approach (though not effective if the correlation is weak) is to evaluate the correlation between short-term and medium-term returns after earnings, identify the pair that exhibits the strongest correlation, and perform the proper trade. For instance, if 1D and 5D display the highest correlation, a trader can place themselves "long" for the forthcoming 5 days if the 1D post-earnings return is favorable. Below is some correlation data based on both a 5-year and a 3-year (more recent) history. Please note that the correlation 1D_5D indicates the relationship between 1D post-earnings returns and subsequent 5D returns. Discover more about Trefis RV strategy that has outperformed its all-cap stocks benchmark (the combination of all 3, the S&P 500, S&P mid-cap, and Russell 2000), providing strong returns for stakeholders. Additionally, if you're seeking upside with a more stable journey than an individual stock like Vertex Pharmaceuticals, think about the High Quality portfolio, which has outperformed the S&P and achieved >91% returns since its inception.
